Home / Health / Pfizer-BioNTech testing booster of their Covid-19 vaccine in new trial

Pfizer-BioNTech testing booster of their Covid-19 vaccine in new trial

The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere

Premium

"The rate of mutations in the current virus is higher than expected," Pfizer Chief Scientific Officer Mikael Dolsten said in an interview | Photo: Shutterstock

Reuters

3 min read Last Updated : Feb 26 2021 | 2:48 AM IST

Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their Covid-19 vaccine to better understand the immune response against new variants of the virus.

They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study.

The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere. But the studies will allow the

Topics : Coronavirus Pfizer Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in